Sébastien S.
- Country
- France
- Department
- Medical Oncology
Research Overview
- Phase I/II Study of TG4050 in Patients with Stage III/IV HPV-Negative Squamous-Cell Carcinoma of the Head and Neck Post-Surgery and Adjuvant Therapy
- Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Evaluation of BI 770371 and Pembrolizumab, With or Without Cetuximab, Versus Pembrolizumab Monotherapy in Head and Neck Squamous Cell Carcinoma Patients
Data & Insights
Has run more than one trial at 245 of 402 partner sites.
Specializations
Head and Neck Cancer Treatment
The investigator specializes in treating various forms of head and neck squamous cell carcinoma (HNSCC), with particular focus on recurrent and metastatic cases. Their research encompasses both early-stage and advanced disease management.
- Locally advanced HNSCC
- HPV-positive and HPV-negative tumors
- Adenoid cystic carcinoma
Immunotherapy Innovation
Their work centers on developing novel immunotherapy combinations, particularly focusing on treatments involving pembrolizumab and other immune checkpoint inhibitors. The research includes investigation of PD-L1 positive cancers and innovative therapeutic approaches.
- Checkpoint inhibitor combinations
- Novel immunotherapy agents
- Targeted therapy combinations
Treatment Modalities
The investigator explores diverse therapeutic approaches including radiotherapy combinations, chemotherapy optimization, and targeted biological therapies. Their work encompasses both curative and palliative treatment strategies.
- Neoadjuvant therapy
- Adjuvant treatment
- Multimodal approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.